Emcure Pharma inks pact to distribute Roche’s select products

Emcure Pharmaceuticals has signed an agreement with Roche to distribute select products from the nephrology and transplant medicine portfolio of the latter.

Effective April 1, under the agreement, it will distribute Roche’s immunosuppressant CellCept as well as Mircera and Neorecormon, which are indicated to treat anemia caused by chronic kidney disease. The move will help expand its portfolio and bring the important medicines to a wider cross-section of patients across the country, Emcure said on Monday.